Search results
Showing 106 to 120 of 1254 results for criteria
Ivonescimab for untreated metastatic non-small-cell lung cancer with high PD-L1 expression
Awaiting development Reference number: GID-TA12444 Expected publication date: TBC
Lutikizumab for treating moderate to severe hidradenitis suppurativa in people 12 years and over
Awaiting development Reference number: GID-TA12446 Expected publication date: TBC
Awaiting development Reference number: GID-TA12461 Expected publication date: TBC
NICE health technology evaluation topic selection: the manual (PMG37)
This manual sets out the process for deciding how topics are identified, selected and routed for NICE guidance developed by the Centre for Health Technology Evaluation (CHTE). This includes diagnostics, highly specialised technologies, interventional procedures, medical technologies and technology appraisal guidance
Awaiting development Reference number: GID-TA11971 Expected publication date: TBC
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Glofitamab for treating relapsed or refractory mantle cell lymphoma
Awaiting development Reference number: GID-TA12447 Expected publication date: TBC
Tozorakimab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease [ID6711]
Awaiting development Reference number: GID-TA11944 Expected publication date: TBC
Agenda and papers of the NICE public board meeting on 19 March 2025
Awaiting development Reference number: GID-TA11987 Expected publication date: TBC
Awaiting development Reference number: GID-TA11976 Expected publication date: TBC
Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745]
Awaiting development Reference number: GID-TA11979 Expected publication date: TBC
Tarlatamab for treating limited-stage small-cell lung cancer after chemoradiotherapy [ID6748]
Awaiting development Reference number: GID-TA11981 Expected publication date: TBC
Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.
Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.